MetaVia

MetaVia Equity

The The Equity of MetaVia (MTVA) as of Oct 30, 2026 is 5.33 M USD. In the previous year, The Equity was 7.93 M USD — a change of -32.76% (lower).

Equity

5.33 MUSD

YoY

-32.76%

Last updated:

In 2025, MetaVia's equity was 5.33 M USD, a -32.76% increase from the 7.93 M USD equity in the previous year.

The MetaVia Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-13.29 M USD
Jan 1, 2019
12.29 M USD
Jan 1, 2020
7.20 M USD
Jan 1, 2021
14.60 M USD
Jan 1, 2022
21.75 M USD
Jan 1, 2023
16.69 M USD
Jan 1, 2024
7.93 M USD
Jan 1, 2025
5.33 M USD
The MetaVia Equity history
YEAREquityYoY
5.33 MUSD-32.76%
7.93 MUSD-52.47%
16.69 MUSD-23.29%
21.75 MUSD+49.00%
14.60 MUSD+102.65%
7.20 MUSD-41.40%
12.29 MUSD-192.52%
-13.29 MUSD-437.12%
3.94 MUSD-80.90%
20.63 MUSD-266.66%
-12.38 MUSD+2,231.45%
-531,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Equity Details

Analyzing MetaVia's Equity

MetaVia's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding MetaVia's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating MetaVia's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

MetaVia's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in MetaVia’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about MetaVia stock

The Equity of MetaVia is 5.33 M USD in 2025.

The Equity of MetaVia changed from 7.93 M USD to 5.33 M USD, representing a -32.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity MetaVia since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's MetaVia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MetaVia

All Key Metrics — MetaVia